Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirze...

Descripción completa

Detalles Bibliográficos
Autores principales: MacIsaac, Richard J., Deed, Gary, D’Emden, Michael, Ekinci, Elif I., Hocking, Samantha, Sumithran, Priya, Rasalam, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597955/
https://www.ncbi.nlm.nih.gov/pubmed/37824027
http://dx.doi.org/10.1007/s13300-023-01475-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597955/
https://www.ncbi.nlm.nih.gov/pubmed/37824027
http://dx.doi.org/10.1007/s13300-023-01475-5

Ejemplares similares